Q2 FY26 results: Revenue up 34.5 percent YoY, H1 PAT up 27.8 percent

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionResults View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.2%Reaction day

₹393.70

prior close

₹399.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-4.6% vs market

Pharmaceuticals peers, median of 156sector-0.0%-4.2% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-0.5

15m

-1.0

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.2+0.4-4.6-0.0-4.2

Next day

+0.3+0.0+0.3-0.7+1.0

+3.6-0.2+3.9-1.0+4.6

+1.6+0.7+0.9+0.1+1.5

+1.6+0.6+1.0+0.2+1.4

-0.6+0.5-1.1+0.0-0.6

+2.4+0.3+2.1-0.3+2.7

15d

-4.5-1.5-3.0-1.6-2.9

-9.1-6.6-2.6-5.3-3.8

+1.4-3.2+4.6-2.9+4.3

+24.0-5.2+29.1-7.4+31.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare posted Q2 FY26 standalone revenue of Rs 57.56 cr, up 34.5 percent YoY from Rs 42.78 cr. PAT was Rs 4.54 cr versus Rs 4.80 cr last year. H1 FY26 revenue grew 31.4 percent to Rs 110.30 cr, with PAT up 27.8 percent at Rs 9.21 cr. H1 EPS stood at Rs 4.14. Operating cashflow rose to Rs 30.59 cr from Rs 21.10 cr. Results were reviewed by J S Shah and Co with an unmodified limited review opinion.

Likely market impact

Strong topline growth in H1, but Q2 PAT slipped and margins compressed. Overall healthy half-year performance with rising operating cashflow.